#AS­CO19: Sanofi sets the stage for a late ar­rival of their mul­ti­ple myelo­ma drug isat­ux­imab — with J&J and Gen­mab lay­ing in wait

CHICA­GO — Phar­ma gi­ant Sanofi is mak­ing a rare ap­pear­ance in the front ranks of the news­mak­ers at AS­CO this year with the de­tails on their Phase III suc­cess sto­ry for their mul­ti­ple myelo­ma drug isat­ux­imab.

We al­ready knew that the da­ta were in their fa­vor. But we didn’t know the ac­tu­al re­sults, which set the stage for a like­ly near-term ap­proval in the US and Eu­rope, where reg­u­la­tors have field­ed their ap­pli­ca­tions for a first OK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER